This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma
by Zacks Equity Research
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
by Zacks Equity Research
Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.
Lilly Reports Mixed Results from Late-Stage Cyramza Study
by Zacks Equity Research
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
by Arpita Dutt
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Pfizer Reports Updated Data from Phase III Study on Ibrance
by Zacks Equity Research
Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.
Lilly's (LLY) Taltz Gets Approval for Label Expansion in US
by Zacks Equity Research
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up in the year so far on rapid pipeline progress plus positive study data and strategic collaborations.
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU
by Zacks Equity Research
This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.
Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry
by Zacks Equity Research
Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.
Lilly Inks Deal to Include Dexcom Products in Diabetes System
by Zacks Equity Research
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.
DexCom-Lily Partnership to Boost CGM Platform, Customer Base
by Zacks Equity Research
DexCom (DXCM) continues to sign deals to boost CGM platform adoption.
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion
by Zacks Equity Research
Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
United Therapeutics PAH Drug's Exclusivity Period Extended
by Zacks Equity Research
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
by Zacks Equity Research
AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
by Arpita Dutt
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
J&J Presents Positive New Data for Diabetes Drug Invokana
by Zacks Equity Research
Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.
Pharma ETFs Down Post Q3 Earnings
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.
Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus
by Zacks Equity Research
Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.
Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal
by Zacks Equity Research
Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.
AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong
by Zacks Equity Research
Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.
Will Radius Health (RDUS) Disappoint This Earnings Season?
by Zacks Equity Research
Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.
Key Predictions for Q3 Earnings Reports of ABBV, MRK
by Zacks Equity Research
The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.